HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Taskinen, M.-R. Articles by Nikkilä, E. A. Search for Related Content PubMed Articles by Taskinen, M.-R. Articles by Nikkilä, E. A.

Serum lipids and Lipoproteins in type 2 diabetes

ABSTRACT. Serum lipids, lipoproteins and lipolytic enzymes were studied (a) before and (b) after six weeks of glipizide treatment in ten (4 men, 6 women) newly diagnosed type 2 diabetic patients. Improved glycemic control during glipizide therapy (HbA₁:11.2±0.5 % vs 9.6 ± 0.4%;P<0.01)had no effect on serum or lipoprotein triglyceride, whereas both serum total cholesterol (4.60 ± 0.29 mmol/l vs 4.37 ± 0.30 mmol/l; P<0.05) and LDL cholesterol (3.16 ± 0.18 mmol/l vs 2.98 ± 0.24 mmol/l; P<0.05) decreased after six weeks of glipizide. HDL cholesterol, the composition and concentration of HDL subfractions HDL₂ and HDL₃ and lipolytic enzymes were uninfluenced by glipizide therapy. In conclusion, low HDL levels in type 2 diabetic patients do not appear to be due to sulphonylurea treatment, but rather represent a basic abnormality of HDL metabolism.